Quanqi (125SER) / Grit Biotechnology, Shandong Quangang Pharma - LARVOL DELTA

GRIT and Quangang Forge Strategic Partnership to Accelerate Localization of Interleukin-2 (PRNewswire) - "Shanghai Grit Biotechnology Co., Ltd...and Shandong Quangang Pharmaceutical...announced the establishment of a formal strategic partnership to leverage both parties' R&D capabilities in innovative T-cell therapy. The objective is to jointly develop a globally standardized IL-2 for solid tumor patients receiving T-cell therapy, aiming to localize the global standard IL-2 with accessible prices for Chinese patients...The focus of the collaboration will be on expanding the indications of Quanqi (125SER) Interleukin-2 (I) products for solid tumors...Both parties will collaborate to develop a domestically produced substitute to the globally recognized immune-regulating cytokine IL-2 in T-cell therapy, addressing the significant unmet medical needs for Chinese cancer patients....Grit's non-gene-engineered TIL program GT101 is in Phase 2 (pivotal) trial -- it is the fastest TIL pipeline in China and plans for BLA filing in 2025."

China filing • Licensing / partnership • Oncology • Solid Tumor